Silverfin false false 31/03/2026 01/04/2025 31/03/2026 Gillian Egan Richard Paul Carton Egan 04/07/2025 14/08/2003 13 May 2026 The principal activity of the company in the year under review was that of specialist supplies to dentists. 04867449 2026-03-31 04867449 bus:Director2 2026-03-31 04867449 2025-03-31 04867449 core:CurrentFinancialInstruments 2026-03-31 04867449 core:CurrentFinancialInstruments 2025-03-31 04867449 core:ShareCapital 2026-03-31 04867449 core:ShareCapital 2025-03-31 04867449 core:CapitalRedemptionReserve 2026-03-31 04867449 core:CapitalRedemptionReserve 2025-03-31 04867449 core:RetainedEarningsAccumulatedLosses 2026-03-31 04867449 core:RetainedEarningsAccumulatedLosses 2025-03-31 04867449 core:OtherPropertyPlantEquipment 2025-03-31 04867449 core:OtherPropertyPlantEquipment 2026-03-31 04867449 2024-03-31 04867449 bus:OrdinaryShareClass1 2026-03-31 04867449 2025-04-01 2026-03-31 04867449 bus:FilletedAccounts 2025-04-01 2026-03-31 04867449 bus:SmallEntities 2025-04-01 2026-03-31 04867449 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 04867449 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 04867449 bus:Director1 2025-04-01 2026-03-31 04867449 bus:Director2 2025-04-01 2026-03-31 04867449 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 04867449 2024-04-01 2025-03-31 04867449 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 04867449 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 04867449 (England and Wales)

# EGAN DENTAL LABORATORY LIMITED

### Unaudited Financial Statements
For the financial year ended 31 March 2026
Pages for filing with the registrar

EGAN DENTAL LABORATORY LIMITED

## Unaudited Financial Statements

For the financial year ended 31 March 2026

Contents

EGAN DENTAL LABORATORY LIMITED

## COMPANY INFORMATION

For the financial year ended 31 March 2026
EGAN DENTAL LABORATORY LIMITED

## COMPANY INFORMATION (continued)

For the financial year ended 31 March 2026

DIRECTORS | Gillian Egan
| Richard Paul Carton Egan (Resigned 04 July 2025)

REGISTERED OFFICE | Unit 9
| Canal Side
| Dallamires Lane
| Ripon
| HG4 1TT
| United Kingdom

COMPANY NUMBER | 04867449 (England and Wales)

ACCOUNTANT | Morrell Middleton Ltd
| Wellington House
| Aviator Court
| York
| YO30 4UZ

EGAN DENTAL LABORATORY LIMITED

## BALANCE SHEET

As at 31 March 2026
EGAN DENTAL LABORATORY LIMITED

## BALANCE SHEET (continued)

As at 31 March 2026

| Note | 2026 |  | 2025
|  | £ |  | £
Fixed assets |  |  |  |
Tangible assets | 3 | 41,375 |  | 31,824
|  | 41,375 |  | 31,824
Current assets |  |  |  |
Stocks | 4 | 11,463 |  | 6,414
Debtors | 5 | 64,871 |  | 57,448
Cash at bank and in hand | 6 | 66,332 |  | 80,426
|  | 142,666 |  | 144,288
Creditors: amounts falling due within one year | 7 | ( 134,495) |  | ( 133,332)
Net current assets |  | 8,171 |  | 10,956
Total assets less current liabilities |  | 49,546 |  | 42,780
Provision for liabilities | 8 | ( 10,344) |  | ( 7,956)
Net assets |  | 39,202 |  | 34,824
Capital and reserves |  |  |  |
Called-up share capital | 9 | 50 |  | 100
Capital redemption reserve |  | 50 |  | 0
Profit and loss account |  | 39,102 |  | 34,724
Total shareholders' funds |  | 39,202 |  | 34,824

For the financial year ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
- These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Egan Dental Laboratory Limited (registered number: 04867449) were approved and authorised for issue by the Director on 13 May 2026. They were signed on its behalf by:

Gillian Egan Director |

EGAN DENTAL LABORATORY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
EGAN DENTAL LABORATORY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026

##### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

##### General information and basis of accounting

Egan Dental Laboratory Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Unit 9, Canal Side, Dallamires Lane, Ripon, HG4 1TT, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

##### Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

##### Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

##### Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Statement of Income and Retained Earnings in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

##### Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

##### Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. | 15 - 25 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

##### Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

##### Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

##### Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).
When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

#### 2. Employees

| 2026 |  | 2025
| Number |  | Number
Monthly average number of persons employed by the Company during the year, including the director | 5 |  | 4

#### 3. Tangible assets

| Plant and machinery etc. |  | Total
| £ |  | £
Cost |  |  |
At 01 April 2025 | 68,142 |  | 68,142
Additions | 18,718 |  | 18,718
Disposals | ( 3,180) |  | ( 3,180)
At 31 March 2026 | 83,680 |  | 83,680
Accumulated depreciation |  |  |
At 01 April 2025 | 36,318 |  | 36,318
Charge for the financial year | 8,497 |  | 8,497
Disposals | ( 2,510) |  | ( 2,510)
At 31 March 2026 | 42,305 |  | 42,305
Net book value |  |  |
At 31 March 2026 | 41,375 |  | 41,375
At 31 March 2025 | 31,824 |  | 31,824

#### 4. Stocks

| 2026 |  | 2025
| £ |  | £
Stocks | 11,463 |  | 6,414

#### 5. Debtors

| 2026 |  | 2025
| £ |  | £
Trade debtors | 61,981 |  | 55,438
Other debtors | 2,890 |  | 2,010
| 64,871 |  | 57,448

#### 6. Cash and cash equivalents

| 2026 |  | 2025
| £ |  | £
Cash at bank and in hand | 66,332 |  | 80,426

#### 7. Creditors: amounts falling due within one year

| 2026 |  | 2025
| £ |  | £
Trade creditors | 7,851 |  | 7,351
Taxation and social security | 64,415 |  | 59,541
Other creditors | 62,229 |  | 66,440
| 134,495 |  | 133,332

#### 8. Deferred tax

| 2026 |  | 2025
| £ |  | £
At the beginning of financial year | ( 7,956) |  | ( 6,107)
Charged to the Statement of Income and Retained Earnings | ( 2,388) |  | ( 1,849)
At the end of financial year | ( 10,344) |  | ( 7,956)

#### 9. Called-up share capital

| 2026 |  | 2025
| £ |  | £
Allotted, called-up and fully-paid |  |  |
50 Ordinary shares of £ 1.00 each (2025: 100 shares of £ 1.00 each) | 50 |  | 100

On 18 September 2025 50 ordinary shares with an aggregate nominal value of £50 were purchased by the company, and subsequently cancelled. The ordinary shares were acquired for a consideration of £73,365, at an average price of £1,460 per share. The consideration includes stamp duty.